Covered recipient · General Payments record
JENNIE LUNA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$2,695.76
- Reported across 96 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $479.43 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $290.51 | 10 |
| Lilly USA, LLC | $108.14 | 5 |
| VIVUS LLC | $63.76 | 3 |
| Currax Pharmaceuticals LLC | $17.02 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $17.02 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089511652 | CMS |
| Lilly USA, LLC | $14.82 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135040203 | CMS |
| Lilly USA, LLC | $27.65 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135040205 | CMS |
| Lilly USA, LLC | $27.58 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135013433 | CMS |
| Lilly USA, LLC | $20.61 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135056678 | CMS |
| Lilly USA, LLC | $17.48 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135061365 | CMS |
| Novo Nordisk Inc | $15.72 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096877370 | CMS |
| Novo Nordisk Inc | $14.83 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096605487 | CMS |
| Novo Nordisk Inc | $59.87 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097192473 | CMS |
| Novo Nordisk Inc | $23.93 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096674206 | CMS |
| Novo Nordisk Inc | $5.85 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096882497 | CMS |
| Novo Nordisk Inc | $16.85 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097715963 | CMS |
| Novo Nordisk Inc | $74.38 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096691364 | CMS |
| Novo Nordisk Inc | $9.10 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096939205 | CMS |
| Novo Nordisk Inc | $52.12 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097479167 | CMS |
| Novo Nordisk Inc | $17.86 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096811543 | CMS |
| VIVUS LLC | $21.97 | 01/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129416806 | CMS |
| VIVUS LLC | $19.62 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129416808 | CMS |
| VIVUS LLC | $22.17 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129416810 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.